摘要 :
Organizations that are using the CERT. Resilience Management Model and organizations that are considering using it want information about the business value of implementing resilience processes and practices, and how to determine ...
展开
Organizations that are using the CERT. Resilience Management Model and organizations that are considering using it want information about the business value of implementing resilience processes and practices, and how to determine which ones to implement. This report describes the SEI research study that begins to address this need. It includes a discussion of the completed phase 1 study and a proposed phase 2 project. Phase 1 included forming a hypothesis and set of research questions and using a variety of techniques to collect data and evaluate whether resilience practices have a discernible (measurable) effect on operational resilience--that is, an organization's ability to continue to carry out its mission (provide critical services) in the presence of operational stress and disruption. The outcomes of phase 1 provide the foundation for the proposed phase 2. The longer term goal includes developing a quantitative, validated business case for prioritizing and implementing specific resilience practices, including decision criteria for selecting and measuring investments in improved resilience.
收起
摘要 :
The Agency for Healthcare Research and Quality (AHRQ) Effective Healthcare (EHC) Program has noted the challenge of decisionmaking when evidence of safety and effectiveness is in dispute and, along with others, has identified the ...
展开
The Agency for Healthcare Research and Quality (AHRQ) Effective Healthcare (EHC) Program has noted the challenge of decisionmaking when evidence of safety and effectiveness is in dispute and, along with others, has identified the importance of values, preferences, and other contextual factors as part of the decision-making process. Stakeholders have played a significant and important role in identifying ways to make comparative effectiveness reviews more useful to decisionmakers by providing input on the needs of the diverse audience of stakeholders when evidence of safety and effectiveness is weak or uncertain. This paper discusses the valuable input that members of the EHC Program Product Development Workgroup provided regarding several key programmatic and content areas, including: report enhancements designed to support decision making when evidence of safety and effectiveness is limited, weak, or conflicting; improvements to the readability and accessibility of program reports; and enhancements to the future research sections of report.
收起
摘要 :
This report describes a collection of monoclonal antibodies that are candidates for use in radioimmunotherapy towards neoplasms of the gastrointestinal tract, breast, or of astrocytomas. In addition a large series of candidate rad...
展开
This report describes a collection of monoclonal antibodies that are candidates for use in radioimmunotherapy towards neoplasms of the gastrointestinal tract, breast, or of astrocytomas. In addition a large series of candidate radionuclides to conjugate to antibodies for therapeutic uses are discussed with respect to potential therapeutic utility and to means of radionuclide production.
收起
